Brief: Histogen Says First Patient Dosed In Phase 1B/2A Trial Of HSt 001 For Androgenic Alopecia
01/06/2020 13:07
June 1 (Reuters) - Histogen Inc HSTO.O :
* HISTOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A
TRIAL OF
HST 001 FOR ANDROGENIC ALOPECIA
Source text for Eikon: ID:nGNX9Mc27R
Further company coverage: HSTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up